Core Viewpoint - Frontier Biotech (688221.SH) reported a total operating revenue of 1,436.687 million yuan for the year 2025, reflecting a year-on-year growth of 10.96% driven by sales of innovative HIV drug Aikening® (generic name: Abacavir), the agency product Veklury® (remdesivir), and the newly approved far-infrared therapy patch Xiaoyan Yipian® [1] Financial Performance - The company recorded a net loss attributable to shareholders of the parent company amounting to 261.7174 million yuan, which is an increase in loss by 60.3348 million yuan compared to the previous year, primarily due to the absence of investment income from the disposal of subsidiary equity that generated 71.8365 million yuan in the previous year [1] - The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 296.2409 million yuan, which is a reduction in loss by 31.0703 million yuan year-on-year, mainly due to the increase in operating revenue and a decrease in period expenses [1]

Core Viewpoint - Frontier Biotech (688221.SH) expects to achieve a revenue of approximately 140 million to 145 million yuan in 2025, representing a year-on-year increase of 8.13% to 11.99%, primarily driven by sales of its innovative HIV drug Aikening® (generic name: Abacavir), the agency product Viread® (Tenofovir Disoproxil Fumarate), and the newly approved far-infrared therapy patch (Xiaoyan Yipian®) [1] Revenue Forecast - The company anticipates that its revenue for 2025 will be between 140 million and 145 million yuan, reflecting a growth of 8.13% to 11.99% compared to the previous year [1] - The revenue growth is mainly attributed to the sales of Aikening®, Viread®, and the newly approved far-infrared therapy patch [1] Profit Forecast - The company projects a net loss attributable to shareholders of approximately 255 million to 290 million yuan for 2025, which is an increase in loss of about 53.62 million to 88.62 million yuan [1] - This increase in loss is primarily due to the absence of investment income from the disposal of subsidiary equity, which generated 71.84 million yuan in 2024 [1] - The expected net loss attributable to shareholders after excluding non-recurring gains and losses is estimated to be between 288 million and 323 million yuan, reflecting a reduction in loss of approximately 4.31 million to 39.31 million yuan, mainly due to revenue growth and reduced operating expenses [1]